Suppr超能文献

血清神经丝轻链浓度升高提示吉兰-巴雷综合征预后不良。

Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.

机构信息

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.

出版信息

J Neuroinflammation. 2020 Mar 17;17(1):86. doi: 10.1186/s12974-020-01737-0.

Abstract

BACKGROUND

Guillain-Barré syndrome (GBS) is an autoimmune disease that results in demyelination and axonal damage. Five percent of patients die and 20% remain significantly disabled on recovery. Recovery is slow in most cases and eventual disability is difficult to predict, especially early in the disease. Blood or cerebrospinal fluid (CSF) biomarkers that could help identify patients at risk of poor outcome are required. We measured serum neurofilament light chain (sNfL) concentrations from blood taken upon admission and investigated a correlation between sNfL and clinical outcome.

METHODS

Baseline sNfL levels in 27 GBS patients were compared with a control group of 22 patients with diagnoses not suggestive of any axonal damage. Clinical outcome parameters for GBS patients included (i) the Hughes Functional Score (HFS) at admission, nadir, and discharge; (ii) the number of days hospitalised; and (iii) whether intensive care was necessary.

RESULTS

The median sNfL concentration in our GBS sample on admission was 85.5 pg/ml versus 9.1 pg/ml in controls. A twofold increase in sNfL concentration at baseline was associated with an HFS increase of 0.6 at nadir and reduced the likelihood of discharge with favourable outcome by a factor of almost three. Higher sNfL levels upon admission correlated well with hospitalisation time (r = 0.69, p < 0.0001), during which transfer to intensive care occurred more frequently at an odds ratio of 2.4. Patients with baseline sNfL levels below 85.5 pg/ml had a 93% chance of being discharged with an unimpaired walking ability.

CONCLUSIONS

sNfL levels measured at hospital admission correlated with clinical outcome in GBS patients. These results represent amounts of acute axonal damage and reflect mechanisms resulting in disability in GBS. Thus, sNfL may serve as a convenient blood-borne biomarker to personalise patient care by identifying those at higher risk of poor outcome.

摘要

背景

吉兰-巴雷综合征(GBS)是一种自身免疫性疾病,可导致脱髓鞘和轴索损伤。5%的患者死亡,20%的患者在康复后仍存在显著残疾。大多数情况下康复缓慢,尤其是在疾病早期,最终残疾程度难以预测。需要血液或脑脊液(CSF)生物标志物来帮助识别预后不良的患者。我们测量了入院时采集的血清神经丝轻链(sNfL)浓度,并研究了 sNfL 与临床结局之间的相关性。

方法

将 27 例 GBS 患者的基线 sNfL 水平与 22 例无轴索损伤诊断的对照组进行比较。GBS 患者的临床结局参数包括:(i)入院时、最低时和出院时的休斯功能评分(HFS);(ii)住院天数;以及(iii)是否需要重症监护。

结果

我们的 GBS 样本入院时的中位 sNfL 浓度为 85.5pg/ml,而对照组为 9.1pg/ml。基线时 sNfL 浓度增加两倍与最低时 HFS 增加 0.6 相关,使出院时预后良好的可能性降低近三倍。入院时较高的 sNfL 水平与住院时间相关性良好(r=0.69,p<0.0001),在此期间,因更频繁发生需要转入重症监护而住院时间延长的几率为 2.4。基线 sNfL 水平低于 85.5pg/ml 的患者有 93%的可能性出院时行走能力不受影响。

结论

入院时测量的 sNfL 水平与 GBS 患者的临床结局相关。这些结果代表了急性轴索损伤的程度,并反映了导致 GBS 患者残疾的机制。因此,sNfL 可能作为一种方便的血液生物标志物,通过识别预后不良风险较高的患者来实现患者护理的个体化。

相似文献

1
Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.
J Neuroinflammation. 2020 Mar 17;17(1):86. doi: 10.1186/s12974-020-01737-0.
2
Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome.
Ann Clin Transl Neurol. 2020 Nov;7(11):2213-2220. doi: 10.1002/acn3.51207. Epub 2020 Oct 8.
3
Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.
J Neurol Neurosurg Psychiatry. 2020 Nov 5. doi: 10.1136/jnnp-2020-323899.
5
Serum Neurofilament Light Predicts Severity and Prognosis in Patients with Ischemic Stroke.
Neurotox Res. 2020 Apr;37(4):987-995. doi: 10.1007/s12640-019-00159-y. Epub 2020 Jan 2.
6
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.
7
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome.
J Neurol. 2024 Nov;271(11):7282-7293. doi: 10.1007/s00415-024-12679-5. Epub 2024 Sep 9.
8
Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.
J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2242-2249. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008. Epub 2019 May 28.
10
Elevated blood and cerebrospinal fluid glucose levels affect the severity and short-term prognosis of Guillain-Barré syndrome.
Neurol Res. 2022 Feb;44(2):121-127. doi: 10.1080/01616412.2021.1965337. Epub 2021 Aug 12.

引用本文的文献

4
Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management.
Neurol Neuroimmunol Neuroinflamm. 2025 Jul;12(4):e200427. doi: 10.1212/NXI.0000000000200427. Epub 2025 Jun 18.
5
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome.
Neurol Neuroimmunol Neuroinflamm. 2025 Jul;12(4):e200419. doi: 10.1212/NXI.0000000000200419. Epub 2025 Jun 5.
6
Critical insights for intensivists on Guillain-Barré syndrome.
Ann Intensive Care. 2025 May 21;15(1):67. doi: 10.1186/s13613-025-01464-w.
10
Guillain-Barré Syndrome Complicated by Severe Acute Respiratory Distress Syndrome: A Case Report.
Int Med Case Rep J. 2024 Sep 27;17:809-817. doi: 10.2147/IMCRJ.S462543. eCollection 2024.

本文引用的文献

2
Neurofilament light chain as a biomarker in neurological disorders.
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. doi: 10.1136/jnnp-2018-320106. Epub 2019 Apr 9.
3
Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank.
Biopreserv Biobank. 2018 Dec;16(6):477-482. doi: 10.1089/bio.2018.0032. Epub 2018 Oct 18.
4
Neurofilaments as biomarkers in neurological disorders.
Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z.
5
Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies.
J Peripher Nerv Syst. 2018 Sep;23(3):174-177. doi: 10.1111/jns.12279. Epub 2018 Jul 24.
6
Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
Lancet Neurol. 2018 Jun;17(6):519-529. doi: 10.1016/S1474-4422(18)30114-5. Epub 2018 Apr 21.
8
9
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.
10
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
JAMA Neurol. 2017 May 1;74(5):557-566. doi: 10.1001/jamaneurol.2016.6117.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验